Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting
01 avr. 2019 13h05 HE
|
Autolus Therapeutics plc
Initial results from the trial show 88% molecular complete response at one month with well-tolerated safety profile Management to Hold Conference Call on April 2, 2019 at 8:00am ET / 1:00pm BST ...
Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
29 mars 2019 16h03 HE
|
Autolus Therapeutics plc
LONDON, March 29, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...